The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer

June 27, 2017
Alexandra S. Zimmer, MD

Alexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.